

Type 2 Diabetes in adults (medicines update) Committee meeting 11 Day 1

Date: 05/09/2024



Location: Hybrid, NICE London Office

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for notes 1 – 6
Chirag Bakhai	Present for notes 1 – 6
Catherine Bewsey	Present for notes 1 – 6
Mimi Chen	Present for notes 1 – 6
Hussain Contractor	Present for notes 1 – 6
Hugh Gallagher	Present for notes 1 – 6
Natasha Jacques	Present for notes 1 – 6
Sallianne Kavanagh	Present for notes 1 – 6
Soon Song	Present for notes 1 – 6
Annette Swinkels	Present for notes 1 – 6
Dominic Taylor	Present for notes 1 – 6

In attendance:		
Sarah Dwyer	Technical Analyst	Present for notes 1 – 6
James Hawkins	Health Economics Adviser	Present for notes 1 – 6
Lina Manounah	Technical Analyst	Present for notes 1 – 6
Sarah Matthews	Technical Analyst	Present for notes 1 – 6
Gregory Moran	Medicines Analyst	Present for notes 1 – 6
Patrick Muller	Health Economics Adviser	Present for notes 1 – 6
Caroline Mulvihill	Topic Lead	Present for notes 1 – 6
Sade Naku	Health Economist	Present for notes 1 – 6
Adam O'Keefe	Project Manager	Present for notes 1 – 6
Lesley Owen	Health Economics Adviser	Present for notes 1 – 6
Muksitur Rahman	Health Economist	Present for notes 1 – 6
Emily Terrazas-Cruz	Senior Technical Analyst	Present for notes 1 – 6
Philip Williams	Finance Analyst	Present for notes 1 – 6

George Wood	Senior Technical Analyst	Present for notes 1 – 6
Jonathan Wray	Senior Analyst	Present for notes 1 – 6

NICE observers:

Patrick Langford	Technical Analyst, Centre for Guidelines	Present for notes 1 – 6
Peter Shearn	Senior Technical Analyst, Centre for Guidelines	Present for notes 1 – 6
Magdalena Watras	Medicines Advisor	Present for notes 1 – 6

Apologies:

Neel Basudev	Committee member
Sithembile Thokozile Chinaire	Committee member
Anne Dornhorst	Committee member
Dan Cuthbertson	Topic Adviser
Sharon McCarthy	Committee member
John Turner	Committee member
Gosia Wamil	Committee member
Astrid Aregui	Senior Medical Editor, NICE
Sarah Glover	Information Specialist, NICE
Nancy Pursey	Assistant Technical Analyst, NICE

1. Welcome, introductions and apologies

The Chair welcomed the Committee members and attendees to Day one of the eleventh meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked committee members to verbally declare any new interests, these are noted below:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Natasha Jacques	Committee member,	Bank project work relating to Diabetes	Direct financial	Declare and participate

	Pharmacist	with former employer NHS Arden and Greater East Midlands Commissioning Support Unit		Rationale: Employment within the NHS
Soon Song	Committee member, Consultant Diabetologist	Invited commentary accepted for publication in Lancet Diabetes and Endocrinology. Song SH, Frier BM. Young adult-onset type 2 diabetes: a high-risk phenotype for complications and mortality. Lancet Diabetes Endocrinol 2024 (in press)	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update
Soon Song	Committee member, Consultant Diabetologist	Presenting abstract entitled 'Severe hypoglycaemia and diabetic ketoacidosis presenting to a hospital emergency department: young-onset type 2 diabetes has poorer prognosis than type 1 diabetes' at the 60th EASD Annual Meeting, Madrid.	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update
Sallianne Kavanagh	Committee member, Pharmacist	Appointed as contracted consultant for WHO Diabetes Compact. Role and outputs: Review quality and participate in meetings of technical reports/systematic reviews in preparation for the guideline meetings. Related to guideline development for type 1 diabetes in	Direct financial	Declare and participate Not specific to the scope of the guideline update

		children.		
Mimi Chen	Committee member, Consultant Diabetologist	Poster presentation at BSPED - British society of paediatric endocrine and diabetes on DNA rate affecting HbA1c.	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update
The Chair and a senior member of the Developer's team noted that otherwise, the interests declared did not prevent the attendees from fully participating in the meeting.				
3. Minutes of previous meeting				
The minutes of the previous meeting were accepted as a true and accurate record, with one minor correction required.				
4. Health economics: Presentation and discussion of final Health economic model results				
<p>The Chair introduced NICE Health Economics Adviser James Hawkins, Health Economist Sade Naku and Health Economist Muksitur Rahman who presented the committee with final results from the Health Economic model developed in support of the guideline update.</p> <p>The committee discussed the results and had the opportunity to ask questions.</p> <p>The Chair thanked the Health Economics team for their hard work developing the model.</p>				
5. Real World Evidence presentation and discussion				
The Chair introduced NICE Health Economics Advisers Patrick Muller and Lesley Owen and Senior Analyst Jonathan Wray and Lesley Owen who presented the committee with real world evidence of health inequalities in diabetes care.				
6. AOB				
The Chair reminded the group that Day two of the meeting is scheduled to commence at 09:30 the following day, thanked participants and closed the meeting.				

Type 2 Diabetes in adults (medicines update) Committee meeting 11 Day 2

Date: 06/09/2024

Location: Hybrid, NICE London Office

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for notes 1 – 6
Chirag Bakhai	Present for notes 1 – 6
Catherine Bewsey	Present for notes 1 – 6
Mimi Chen	Present for notes 1 – 6
Hussain Contractor	Present for notes 1 – 6
Anne Dornhorst	Present for notes 1 – 6
Natasha Jacques	Present for notes 1 – 4
Sallianne Kavanagh	Present for notes 1 – 6
Soon Song	Present for notes 1 – 6
Annette Swinkels	Present for notes 1 – 6
Dominic Taylor	Present for notes 1 – 6

In attendance:		
Astrid Aregui	Senior Medical Editor	Present until partway through item 4
Sarah Dwyer	Technical Analyst	Present for notes 1 – 6
James Hawkins	Health Economics Adviser	Present for notes 1 – 6
Lina Manounah	Technical Analyst	Present for notes 1 – 6
Sarah Matthews	Technical Analyst	Present for notes 1 – 6
Gregory Moran	Medicines Analyst	Present for notes 1 – 6
Patrick Muller	Health Economics Adviser	Present for item 4
Caroline Mulvihill	Technical Adviser, Guideline Lead	Present for notes 1 – 6
Sade Naku	Health Economist	Present for notes 1 – 6
Adam O’Keefe	Project Manager	Present for notes 1 – 6
Lesley Owen	Health Economics Adviser	Present for notes 1 – 6
Nancy Pursey	Assistant Technical Analyst	Present for notes 1 – 6
Muksitur Rahman	Health Economist	Present for notes 1 – 6

Emily Terrazas-Cruz	Senior Technical Analyst	Present for notes 1 – 6
Philip Williams	Finance Analyst	Present for notes 1 – 6
George Wood	Senior Technical Analyst	Present for notes 1 – 6
Jonathan Wray	Senior Analyst	Present until item 3

NICE observers:		
Patrick Langford	Technical Analyst, Centre for Guidelines	Present for notes 1 – 6
Peter Shearn	Senior Technical Analyst, Centre for Guidelines	Present for notes 1 – 6
Magdalena Watras	Medicines Advisor	Present for notes 1 – 6

Apologies:	
Neel Basudev	Committee member
Sithembile Thokozile Chinaire	Committee member
Dan Cuthbertson	Topic Adviser
Hugh Gallagher	Committee member
Sharon McCarthy	Committee member
John Turner	Committee member
Gosia Wamil	Committee member
Sarah Glover	Information Specialist, NICE

1. Welcome, introductions and apologies				
The Chair welcomed the Committee members and attendees to Day two of the eleventh meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.				
2. Confirmation of matter under discussion, and declarations of interest				
The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.				
The Chair asked committee members to verbally declare any new interests, these are noted below:				
Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Anne Dornhorst	Committee member,	Gave talk to Diabetes Federation	Direct, non-financial	Declare and participate

	Consultant Diabetologist	of European Nurses on Agents for Housebound Patients	professional and personal	Not specific to the scope of the guideline update
<p>The Chair and a senior member of the Developer’s team noted that otherwise, the interests declared did not prevent the attendees from fully participating in the meeting.</p>				
<p>Health economics</p>				
<p>The Chair re-introduced NICE Health Economics Adviser James Hawkins, Health Economist Sade Naku and Health Economist Muksitur Rahman who presented the remaining results from the Health Economic model not presented on Day 1 of the meeting.</p> <p>The committee discussed the results and had the opportunity to ask questions.</p>				
<p>3. Recommendation drafting</p>				
<p>The committee considered the results of the Health Economic model presented the previous day and the clinical evidence presented over the course of the guideline development meetings, revisited recommendations drafted previously, and drafted recommendations accordingly</p>				
<p>4. Research recommendations</p>				
<p>Item covered under item 3.</p>				
<p>5. Next steps to consultation</p>				
<p>Adam O’Keefe, Project Manager advised key dates and next steps to the guideline consultation period.</p>				
<p>6. AOB</p>				
<p>The Chair thanked participants for their contributions at this meeting and for during development of the guideline, and closed the meeting.</p>				

Date of next meeting: Post-consultation meeting TBC

Location of next meeting: TBC